Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Nab-Paclitaxel in High Risk Bladder Cancer
NCT02718742Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Jun 2016
- Primary completion
- Jun 2021
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in bladder urothelial carcinoma, sponsored by Mayo Clinic. Primary endpoint: Progression-Free Survival at 6 months. Planned start Jun 2016; status: withdrawn.
02
Drugs
nab-paclitaxel
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT02718742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718742.